Respiratory Syncytial Virus Infections
Conditions
Keywords
RSV infection, Hematopoeitic stem cell transplant
Brief summary
This study tests the effects of an experimental drug PC786 in people infected with Respiratory Syncytial Virus (RSV). PC786 may be useful in treating patients infected with RSV as it works by interfering with the way the virus multiplies. PC786 is an inhaled medicine. Participants will be treated with SoC treatment (e.g. oral ribavirin and/or IV immunoglobulin), half of the participants will receive PC786 in addition and half will receive a placebo treatment. The study will take place at multiple sites in UK and will include approximately 30 participants. The maximum study duration will be about 4 weeks.
Interventions
DRUGPC786
PC786 suspension for inhalation
DRUGPlacebo
Placebo solution for inhalation
DRUGSOC
Standard treatment for RSV infection at study site
Sponsors
Pulmocide Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Received an allogeneic or autologous hematopoietic stem cell transplant (HSCT) using any conditioning regimen * Experienced new onset of at least one of the following respiratory symptoms ≤5 days before study Day 1: Nasal congestion or stuffiness, runny nose (rhinorrhoea), cough, or sore throat OR Worsening of at least one of those symptoms, if symptoms are chronic OR Wheezing, sputum production, pleuritic chest pain, increased respiratory rate, signs on chest auscultation, hypoxia, increased supplemental oxygen requirement or new infiltrates on chest X-ray/CT * A positive RSV diagnostic test * Provided written informed consent
Exclusion criteria
* Is intubated and requires invasive ventilation * Has received any investigational RSV vaccine after HSCT, or has received any monoclonal anti-RSV antibodies within 4 months or 5 half-lives before participation * Treatment with intravenous ribavirin * Positive for test for influenza or parainfluenza * Significant untreated bacteraemia or fungaemia * Significant untreated bacterial, fungal, or viral pneumonia * Precluded from participating as a result of treatment with another investigational drug or participation in another clinical trial * Other disease or condition which would preclude the subject's participation in a clinical trial * Is receiving an antiretroviral protease inhibitor * Has chronic, active hepatitis infection * Known alcohol or drug abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RSV viral load measured in nasal secretions by reverse transcription quantitative PCR (RT-qPCR) | Day 1 to Day 3 |
| Proportion of participants reporting one or more treatment-emergent adverse event (TEAE) | Baseline to Day 28 |
| Proportion of participants who discontinue due to an adverse event | Baseline to Day 28 |
| Proportion of participants who meet the markedly abnormal criteria for 12-lead ECG assessment at lease once post dose | Baseline to Day 28 |
| Proportion of participants who meet the markedly abnormal criteria for vital signs assessment at lease once post dose | Baseline to Day 28 |
| Proportion of participants who meet the markedly abnormal criteria for safety laboratory assessment at lease once post dose | Day 1 to Day 28 |
| Proportion of participants who meet the markedly abnormal criteria for peak expiratory flow assessment at lease once post dose | Day 1 to Day 28 |
Secondary
| Measure | Time frame |
|---|---|
| Last quantifiable concentration (Ct last) of PC786 measured in plasma | Day 1, and multiple timepoints to Day 28 |
| Changes in RSV symptoms measured using a symptom diary card | Days 1, 2, 3, 4, 5, 6, 7, 14 and 28 |
| Average change in RSV load measured in nasal secretion | Day 1 to Day 7 |
| Proportion of participants progressing to invasive ventilation | Day 1 to 28 |
| Trends in oxygen saturation index | Day 1 to Day 7 |
| Proportion of participants developing lower respiratory tract infection (LRTI) or pneumonia | Day 1 to 28 |
| Change in RSV load in nasal secretion | Baseline to Day 3 |
| Duration in viral shedding measured in nasal secretion | Day 1 to Day 28 |
| Determination of nasal concentrations of PC786 | Days 1, 2, 3, 7, 14 and 28 |
| Maximum observed concentration (Cmax) of PC786 measured in plasma | Day 1, Pre-dose to 4 hours |
| Trough plasma concentration (Ctrough) of PC786 | Days 2 and 3, Pre-dose |
| Area under the concentration versus time curve from time zero to time at 4 hours (AUC0-4) of PC786 in plasma | Day 1, Pre-dose to 4 hours |
Countries
United Kingdom
Outcome results
None listed